Kornitzer Capital Management Inc. KS reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 15.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 441,864 shares of the biopharmaceutical company's stock after selling 80,870 shares during the period. Kornitzer Capital Management Inc. KS owned about 0.35% of Halozyme Therapeutics worth $25,292,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the business. Whittier Trust Co. bought a new stake in shares of Halozyme Therapeutics during the first quarter valued at approximately $27,000. GAMMA Investing LLC raised its position in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 254 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth $33,000. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $49,000. Finally, Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics during the third quarter valued at $57,000. Hedge funds and other institutional investors own 97.79% of the company's stock.
In related news, CEO Helen Torley sold 10,000 shares of the business's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $40,063,244.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares of the company's stock, valued at approximately $40,063,244.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Matthew L. Posard sold 9,881 shares of the business's stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now directly owns 69,874 shares in the company, valued at approximately $4,031,729.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 89,881 shares of company stock worth $5,169,834. Company insiders own 2.70% of the company's stock.
A number of equities research analysts recently weighed in on the company. JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research report on Friday, November 1st. Piper Sandler upped their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a research report on Monday. HC Wainwright lifted their target price on shares of Halozyme Therapeutics from $65.00 to $68.00 and gave the company a "buy" rating in a report on Friday, November 1st. Morgan Stanley raised their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an "overweight" rating in a research report on Wednesday, August 7th. Finally, Benchmark restated a "buy" rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $61.11.
Get Our Latest Report on HALO
Shares of HALO stock traded down $1.38 on Thursday, hitting $59.25. 100,436 shares of the stock traded hands, compared to its average volume of 1,284,214. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The stock has a market capitalization of $7.54 billion, a PE ratio of 20.08, a PEG ratio of 0.53 and a beta of 1.29. The firm's 50-day moving average price is $56.75 and its two-hundred day moving average price is $52.48. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.18. The business had revenue of $231.40 million during the quarter, compared to analysts' expectations of $204.94 million. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%. The business's revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.68 EPS. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 3.84 EPS for the current year.
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Halozyme Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.
While Halozyme Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.